Medical Products for Rare Diseases and Conditions

Summary

Article describes the FDA Orphan Drug Designation program for drugs and biologics treating rare diseases affecting fewer than 200,000 people in the U.S. This is a general informational piece about regulatory pathways without specific company or drug announcements.